The new contracts support ReNeuron’s clinical trial activities by the manufacture of additional clinical-grade material (drug substance lots) and the provision of manufacturing process validation services.
Gordon Sherriff, chief operating officer of Angel, said: “We are very pleased to have signed these contracts to provide ReNeuron with additional GMP grade materials and services in support of its ReN001 clinical trial for stroke. Such clinical programmes are complex and require a high level of regulatory compliance.
“Angel’s significant experience and expertise in this rapidly evolving field provides the flexible and regulatory compliant solutions that Biotech and Pharma customers require in the cell therapy arena. Our premier offering has made Angel the leading GMP manufacturer for clinical grade stem cells in the UK and beyond.”